Figure 4.

Systemic delivery of siCCR5 with LFA-1 I-tsNPs protects BLT mice from HIV infection. (a) BLT mice were treated intravenously with either siLuc (n = 3) or siCCR5 (n = 3) complexed to LFA-1 I-tsNPs, infected with HIV_BaL, and monitored for viral load and CD4 counts according to protocol described. (b) Representative dot plots from one siLuc-treated and one siCCR5-treated mouse are shown. (c) Viral copy numbers in plasma measured by the Amplicor test and (d) CD3⁺CD4⁺ T-cell percentages monitored by flow cytometry at various times are shown. CD4 T-cell ratios were calculated as a ratio of the entire CD3 population (CD3⁺CD4⁺/CD3⁺). Individual animals in each group are represented by distinct symbols. HIV, human immunodeficiency virus; I-tsNP, integrin targeted and stabilized nanoparticle; LFA-1, lymphocyte function–associated antigen-1.